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Left ventricular assist device (LVAD) therapy remains a vital therapeutic option for 
patients with end-stage heart failure. Unfortunately, adverse events can occur and 
progress to require consideration for device exchange once the failure of medical 
management becomes evident, especially when heart transplantation is not 
possible in a timely manner. The aim of this analysis is to describe the incidence 
and outcomes of LVAD exchanges at our institution. Between April 2008 and May 
2017, 397 patients underwent LVAD implantation, with 32 of those patients 
subsequently receiving exchange upon the recommendation of our 
multidisciplinary team due to refractory infection (n=12), device malfunction (n=5), 
hemolysis (n=9) and pump thrombosis (n=6). The average time from index implant 
to exchange was 580.6 days, with an average length of stay of 18.2 days. Survival 
at 3 months was 84.4%, 75.0% at 1 year and median at 8.3 years after exchange. 
The most common adverse events, occurring in less than 1/3 of the population, 
included bleeding, infection and stroke. This study suggests that LVAD exchange 
can be an effective and definitive mechanism for the treatment of otherwise 
potential fatal pump complications in highly select patients. 
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Introduction 
Heart failure is the leading cause of hospitalizations annually, with recent 
estimates of Americans 40 years or older facing a 20% lifetime risk, a prevalence 
of over 9 million Americans by 2030. 1 A significant proportion of patients will 
unfortunately go on to fail medical therapy, requiring the use of advanced 
treatment strategies for end-stage heart failure. While many patients at this stage 
can be successfully treated with transplantation, a large number have 
comorbidities that prevent eligibility for the therapy, or have unacceptably 
prolonged wait times, thereby making durable left ventricular assist device (LVAD) 
support their most viable therapeutic option.2-3 However, serious complications 
necessitating device exchange can include pump thrombosis, hemolysis and 
infection, posing challenging management scenarios for those who remain 
ineligible for transplantation after LVAD or have a prolonged wait time and 
experience a complication while on mechanical support. 4 
 
Risk factors for adverse events leading to exchange commonly include deviation 
from standardized implant and immediate/long-term management techniques, 
advanced age, immunosuppressed states such as diabetes, elevated blood 
pressure and patient non-compliance.5-8 Methods to improve outcomes and 
decrease adverse events include careful instruction on routine maintenance of the 
driveline, accurate monitoring of anticoagulant and antiplatelet therapy and 
aggressive antibiotic therapies when indicated (oral and parenteral), guided by 
culture data in consultation with an infectious disease specialist.  
 
Unfortunately, some patients still progress to consideration for LVAD exchange 
once the failure of medical management becomes evident, especially when 
transplantation is not possible in a timely manner. This analysis describes the 




A retrospective analysis of our institution’s LVAD database was performed. During 
a 9-year period, 397 patients underwent LVAD implantation between April 2008 
and May 2017, with 32 of those patients subsequently receiving LVAD exchange 
between September 2009 and March 2017. Only initial pump exchange patients 
were included in the reviewed cohort. The reasons for exchange included: 
refractory infection, evidence of device malfunction, hemolysis and pump 
thrombosis. Surgical approach varied based on device and indication for exchange 
and included subcostal or full sternotomy approaches.  
 
Descriptive analysis, Kaplan-Meier survival estimates and time to first event were 
then calculated. Outcomes of interest included death, hemolysis, pump 
thrombosis, stroke, right heart failure, bleeding and infection.  The time between 
initial implant and exchange, length of post-operative hospital stay, discharge 
location and average time to follow-up after discharge were monitored to provide 
an objective standard for post-operative patient management.The decision to 
exchange the device was defined by the failure of medical therapy as determined 
by an interdisciplinary team of cardiologists, infectious disease specialists and 
surgeons. Specific criteria for exchange in cases of infection included refractory 
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infection as guided by physical examination, laboratory, culture and imaging data 
despite appropriate culture-guided antibiotic therapy. Ongoing laboratory and 
pump parameters were used to define hemolysis and pump thrombosis according 
to the accepted Interagency Registry for Mechanically Assisted Circulatory 
Support (INTERMACS) definitions.3 Infection data, concomitant medications and 
antibiotic history were collected to investigate the most common risk factors and 
pathogens involved and any possible correlations with surgical outcomes. 
The surgical approach focused on incision type – patients required sternotomy 
when complete device extraction was necessary to address their reason for pump 
exchange. In cases of infection, full sternotomy was only performed when infection 




Baseline demographics, surgical approach, reviewed models and patient status 
can be found in Table 1.  
 
Table 1. Baseline Characteristics (HMII - HeartMate, HVAD - Heartware 
Ventricular Assist Device, BTT - Bridge to Transplantation, DT - Destination 
Therapy) 
   Deciding Factor for Exchange 
  
Infection (N = 
12) 
Other (N = 20) 
Demographics 
Age : Average 44.5 52.8 
Gender: Males 10 13 
Race  
Caucasian 12 15  
African American 0 5  
BMI (kg/m2) : Average 32.8 31.2 
VAD Model Exchanges 
   HMII → HMII 9 17 
   HVAD → HVAD 1 2  
   HMII → HVAD 2  1  
Incision Type 
 Subcostal  8 13 
Sternotomy 4 7 
Status 
BTT 6 7 
DT 6 13 
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Reason for exchange in the overall cohort included infection (n=12), hemolysis 
(n=9), pump thrombosis (n=6) and pump malfunction (n=5) (Table 2). Pump 
malfunction included driveline or internal wire fracture (n=2), pump migration (n=2) 
and detachment of outflow graft (n=1). Of note, 71.4% of patients going on to 
exchange were diagnosed and treated for infection during the evaluated timeline. 
The most common infections included Staphylococcus (40%), Pseudomonas 
(11.4%) and Enterococcus (8.6%); however, some patients had more than one 
isolated bacteria responsible for their infections (Table 3). Appropriate antibiotics 
were guided by culture data, with a median treatment course of 184 days before 
exchange. The average time from index implant to exchange was 580.6 days, with 
an average length of stay after exchange of 18.2 days. 
  
Table 2. Deciding Factor for Exchange  
Deciding Factor for 
Exchange 
Infection 12  








Table 3. Organism Culture prior to Exchange (MSSA - Methicillin Sensitive 
Aureus, CoNS - Coagulase Negative Staphylococcus)Staphylococcus 
Aureus, MRSA - Methicillin Resistant Staphylococcus  
 
Organism cultured prior to exchange 
MSSA MRSA CoNS Pseudomonas Acinetobacter Aerococcus 
viridans 
Stenotrophomonas Proteus 
5 2 2 2 1 1 1 1 
*4 patients with double infection at the time of exchange 
 
Twenty-seven patients (77.1%) were discharged directly home following the 
exchange, 5 (14.3%) to a long-term care skilled nursing facility or acute 
rehabilitation unit and 5 died within 90 days. Causes of death included 
intracerebral hemorrhage (2), respiratory failure (1), mycotic aneurysm (1) and 
cardiac arrest (1). Survival at 3 months for the combined cohorts was 84.4%, 
75.0% at 1 year and median 8.3 years after exchange. Survival post exchange for 
the infection group was 92% and 83.% at 3 months and 1 year, respectively, while 
survival  “other” group was 80% and 70% at those same time intervals (Figure 1). 
Adverse events experienced after initial exchange are included in Table 4. The 
most common complications included stroke, recurrent infection and 
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Figure 1. Kaplan Meier Curve of Survival for Infection vs. Other 
The survival post exchange at 3 months is 92% for the infection group, and at 1 
year is 83.%.  Survival post exchange for the ‘other’ group at 3 months is 80%, and 
at 1 year is 70%.  With small sample sizes, p-values were not calculated. The 
overall median survival was > 8.3 years 
Median survival was calculated only within the reviewed time frame. There were 
12 deaths after exchange with average survival time of at least 2.5 years. Within 
the 12 patients exchanged due to infection, there were 3 mortalities with average 
time to death at 1.1 years.  One patient died after 52 days.   
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Table 4. Post Exchange Adverse Events 
Post Exchange Adverse Events (N=32) 
Event N 
Average Time to 
Event (years) 
Hemolysis 4 1.2 
Right Heart Failure 2 1.6 
Other Bleed 4 1.3 
Gastrointestinal Bleeding 7 0.6 
Stroke 12 0.6 
      Transient ischemic Attack 1 0.13      
       Ischemic     3 0.3 
      Intracranial Hemorrhage 8 0.7 




In an era of a growing advanced heart failure population, strategies other than the 
often-limited option of cardiac transplantation must be considered. If LVAD 
utilization increases with this mounting population, so do the potential for 
downstream complications such as pump thrombosis, hemolysis, and infection. 
Even if heart transplantation remains an option for these complex patients after a 
LVAD complication, the appropriate organ may not become available in adequate 
time, risking further deterioration and critical illness.  Our data indicates these 
patients can be safely exchanged with reasonable post-operative courses, short 
post-operative length of stays and positive long-term outcomes, with rates of 
survival in this analysis of re-operative patients being slightly lower than the 
current rates of post-operative survival with continuous flow devices.3 To our 
knowledge, this is the largest study of LVAD exchanges yet to be reported.  
Notably, for the patients with infection, the risks associated with the exchange are 
entirely acceptable in comparison to the risks associated with the near certain 
progression of disseminated infection. Each patient’s historical factors, physical 
characteristics, laboratory, culture and imaging data were used to determine the 
diagnosis and extent of infection. The exchange was only undertaken after an 
interdisciplinary team (representing cardiology, infectious disease, and surgery) 
determined failure of medical therapy. Individual patient characteristics such as 
adherence to medical recommendations, psychosocial factors, surgical history, 
antibiotic history and extent of infection were carefully considered before 
undertaking the task of an exchange. Furthermore, type of bacterial infection and 
the ability for complete eradication by stringent washout before re-implantation of a 
new device with subsequent long-term antibiotics was weighed against any 
potential morbidity or mortality from the procedure, the ability to undergo a full 
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sternotomy if necessary and a shared-decision making process with the 
aforementioned factors in mind.  
  
While the risk factors for exchange are not always clear, we attempt to adhere to 
the instructions for use for the particular LVAD being implanted, inclusive of 
anticoagulation and antiplatelet therapies, as well as the PREVENT 
recommendations for peri-operative and long-term management of HeartMate II 
patients. We pay close attention to the recommendations from the PREVENT 
guidelines for intra-operative considerations, heparin bridging, and pump speeds > 
9,000 RPMs. We also advise patients to change their driveline dressings using 
sterile precautions daily in the early post-operative phase, not shower until fully 
incorporated and change dressings when showering or at least twice weekly 
thereafter. Our infectious disease team assesses patients preoperatively and 
during the immediate post-operative period, and as needed should any infectious 
issues arise. Additionally, many studies demonstrate elevated blood pressure with 
an increased risk of adverse events, with the best examples coming from the 
Heartware VAD populations.10,11 As doppler blood pressure most closely 
approximates systolic blood pressure and mean arterial blood pressure,12 our 
center’s practice is to aim for a goal of <90mm Hg. 
  
While patient adherence is often an issue, modification and attention to the 
specifics of medical management following LVAD implantation can have a 
substantial impact on post-surgical complications and improved quality of life.6 Our 
multidisciplinary team inclusive of surgical, medical, infectious disease, 
hematology, supportive/palliative care, pharmacy, nursing and social work 
colleagues continually re-educate patients on the importance of adherence to best 
practices regarding blood pressure, anticoagulation and driveline management. 
Based on our experience, we propose that LVAD exchanges only be performed 
once such an interdisciplinary committee has convened and determined that a 
device complication is indeed refractory to medical therapy. In preparation for 
exchange, a risk mitigation plan to prevent need for re-exchange must be in place 
to aid in long-term monitoring and support as part of the patient’s treatment plan as 




Not all possible confounding variables were recorded or adjusted for in this study. 
While confounding patient characteristics (compliance, psychosocial barriers and 
financial limitations) were considered during the evaluation for exchange, it is 
difficult to objectively quantify these risk factors as associated with long-term 
outcomes after each exchange. This patient population also experienced careful 
evaluation and counseling by Palliative/Supportive Care Medicine specialists to aid 
in decision making and management of chronic pain, fatigue and distress. This 
counsel may have resulted in the patient opting against device exchange as a 
potential option, particularly if a full exchange was recommended – the exact 
number of patients who opted against exchange in this situation is not available. 
The limited size of this study along with the other stated limitations do not 
necessarily allow these findings to be generalizable to an entire LVAD population. 
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Finally, the retrospective nature of the study contributes to possible bias and 
discrepancies in collecting and reviewing data. 
Clinical Implications  
The results of our study suggest that LVAD exchange can be an effective and 
definitive mechanism for the treatment of otherwise potentially fatal pump 
complications in highly select patients. Complex patients such as those analyzed 
in our cohort can be safely exchanged with outcomes that improve both longevity 
and quality of life. Patients reported ability to complete ADLs, return to work and 
ambulate with more easily allowing further enjoyment of life. No specific, 
formalized quality of life data was uniformly available in this retrospective review. 
Risks associated with the exchange procedure are minimal in comparison to the 
risks associated with the potential for disseminated infection or disease worsening 
arising from ongoing pump malfunction. If patients are continually educated on the 
care of their device and have a reliable support system in place, LVAD exchange 
should be considered in cases where no other solutions are available in a timely 
fashion. 
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